Morphologic change in deep venous thrombosis in the lower extremity after therapeutic anticoagulation

Tanapong Panpikoon*, Wisanu Phattharaprueksa, Tharintorn Treesit, Chinnarat Bua-ngam, Kaewpitcha Pichitpichatkul and Apichaya Sriprachyakul

Abstract

Background: To evaluate the anticoagulant treatment response in venous thrombi with different morphologies (size, shape, and echogenicity) by measuring the change in thrombus thickness.

Materials and methods: This was a retrospective cohort study of 97 lower extremity DVT patients diagnosed by venous ultrasound between March 2014 and February 2018. The demographics, clinical risk factors, anticoagulant treatment, and ultrasound findings at the first diagnosis and 2–6 months after treatment were evaluated.

Results: The anticoagulant treatment with LMWH followed by VKAs showed a significant decrease in the mean maximum difference in lower extremity DVT thrombus thickness compared with VKAs alone (P-value < 0.001). After adjustment by treatment, the thrombi found in dilated veins showed a significant decrease in the thickness of such thrombi compared with those found in small veins: 4 mm vs. 0 mm (Coef. = 3, 95% CI: 1.9, 4.1 and P-value < 0.001). Anechoic and hypoechoic thrombi showed a significant decrease in the thickness compared with hyperechoic thrombi: 5 mm vs. 0 mm (Coef. = 4, 95% CI: 3.25, 4.74 and P-value < 0.001) and 3 mm vs. 0 mm (Coef. = 2, 95% CI: 1.34, 4.26 and P-value < 0.001), respectively. Concentric thrombi showed a significant decrease in thickness compared with eccentric thrombi: 4 mm vs. 0 mm (Coef. = 2, 95% CI: 1.45, 2.55 and P-value < 0.001).

Conclusion: The anticoagulant treatment with LMWH followed by VKAs shows a significant decrease in lower extremity DVT thrombus thickness compared with VKAs alone. After adjustment by treatment, the morphologic finding of acute thrombi shows a significantly decreased thickness compared with the morphologic finding of chronic thrombi.

Keywords: Deep vein thrombosis, Venous duplex ultrasound, Thrombus resolution, Anticoagulant treatment

Introduction

Deep venous thrombosis (DVT), which commonly occurs in the lower extremities and is associated with pulmonary embolism (PE) and referred to together as venous thromboembolism (VTE), is a significant global health burden [1]. Accurate VTE diagnosis is essential due to the morbidity and mortality associated with missed diagnoses and the potential side effects, patient inconvenience, and resource implications of anticoagulant treatment [2].

The diagnosis of VTE based on clinical manifestations alone is unreliable [3]. The D-dimer test for exclusion of DVT, followed by proximal lower extremity ultrasound, is recommended in a population with low pretest probability (PTP) of lower extremity DVT. Initial proximal lower extremity ultrasound followed by whole leg
ultrasound is recommended in a population with intermediate and high PTPs of lower extremity DVT [2].

The diagnostic criteria of DVT are lack of complete cross-sectional vein compressibility or direct visualization of an intraluminal thrombus in B-mode, combined or not combined with colour-Doppler ultrasound. Initial (5–21 days following diagnosis) and long-term (3–6 months following diagnosis) treatment are mandatory for all patients with positive ultrasound for DVT. Extended treatment (beyond the first 3–6 months) is based on the risk/benefit balance of continued anticoagulation, patient compliance and preference [4]. Follow-up venous ultrasound at 3–6 months after coagulation treatment has a role in evaluating recurrent DVT. A 2- or 4-mm increase in venous diameter between two measurements of the common femoral and popliteal veins is the most validated criterion for the diagnosis of recurrent DVT [5].

In addition to thrombus visualization, ultrasound also provides morphological information on the thrombus related to the progression of the thrombus-forming process, namely, fibrin deposition in the first few days, thrombolysis within a week, and fibroblast invasion and capillary development within several weeks [6]. The varied staging of thrombi results in different responses to anticoagulant treatment. Morphological information, such as the size, shape and echogenicity of the thrombus, may be another concerning factor for initial and extended anticoagulation treatment unless the patient’s factors. However, there is no study to support this hypothesis.

The purpose of this study was to evaluate the response of anticoagulation treatment in venous thrombi with different morphologies (size, shape and echogenicity) by measuring the thrombus thickness change between the maximum thickness at the first diagnosis and that at 3–6 months after long-term treatment.

**Materials and methods**

A retrospective cohort study was conducted on lower extremity DVT patients diagnosed by venous ultrasound between March 2014 and February 2018. The demographics, clinical risk factors, anticoagulation treatment, and ultrasound findings at the first diagnosis and 2–6 months after treatment were evaluated. The Institutional Review Board approved the study, and informed consent was waived.

According to the standard protocol, four consultant radiologists with a minimum of 5 years of postqualification experience performed whole leg ultrasound (proximal and distal lower extremity veins). A similar protocol was used in the first diagnosis and follow-up study after anticoagulant treatment.

The protocol of lower extremity venous ultrasound begins with cross-sectional greyscale compression of the common femoral vein (CFV), femoral vein (FV) and popliteal vein (Pop V) at 2-cm intervals. Dual images before and during compression were recorded at CFV, proximal FV, mid-FV, distal FV and the popliteal vein.

The criteria from DVT diagnosis are as follows:

1. Lack of complete compressibility
2. Visualization of an intraluminal thrombus

Suppose the intraluminal thrombus or incomplete compressibility is presented. The anterior-posterior thickness of the thrombus or the incomplete compressed vein will be measured in millimetres (mm). A colour flow image is an option for confirmation of suspicious intraluminal thrombus and complete haemodynamic information. An equivalent technical examination was performed on the calf veins. No video recording was made. A Toshiba Apio 500 ultrasound scanner equipped (Canon Medical Systems Corporation, Japan) with a 14-MHz linear-array transducer (PLT-705BT) was used in the study.

The different thicknesses of venous thrombi between the first diagnosis and 3–6 months after the long-term treatment were remeasured by three radiologists. The mean value of the three measurements was used. The thrombus, which showed the maximum difference in thickness from one of five locations (CFV, prox-FV, mid-FV, dis-FV and the popliteal vein) and one side per patient, was selected for the statistical analysis.

The consensus from three experienced radiologists was used for the morphological classification according to the following criteria:

1. Size (Fig. 1)
   - Increased size; the affected vein is more than two times larger than the adjacent artery.
   - Normal size: the affected vein is equal to or not more than two times larger than the adjacent artery.
   - Decreased size; the affected vein is smaller than the adjacent artery.

2. Echogenicity (Fig. 2)
   - Anechoic; the thrombus appears black on the screen.
   - Hypoechoic; the thrombus appears grey on the screen.
   - Hyperechoic; the thrombus appears white on the screen

3. Shape (Fig. 3)
   - Concentric: the presence of an acute angle between the thrombus and venous wall or total occlusion
   - Eccentric: the presence of an obtuse angle between the thrombus and venous wall.
Patient selection

**Inclusion criteria**

- Lower extremity DVT patients were diagnosed, treated and followed by the venous ultrasound from March 2014 to February 2019.

**Exclusion criteria**

- Patients whose sonographic image were inadequate for interpretation.
- Patients with isolated DVT in the calf vein.
- Patients younger than 18 years old.

**Statistical analysis**

Categorical variables and clinical and sonographic characteristics were evaluated. Normally distributed data are presented as the mean and standard deviation. Nonnormally distributed data are presented as the median and range. The comparison was performed by median regression analysis between morphologic findings and the maximum difference in thrombus thickness. Multiple median regression analyses were applied to individual variables (treatment and the timing of the repeat ultrasound). Analytical results are presented as a coefficient and 95% confidence intervals (CI). A \( p \)-value of < 0.05 was considered statistically significant. STATA version 15.1 (Stata Corp, College Drive, Texas) statistical software was used to analyse the data.

**Results**

Between March 2014 and February 2019, 106 lower extremity DVT patients were diagnosed and followed by venous ultrasound. Four patients were excluded from the study due to inadequate sonographic imaging for interpretation, and five patients were excluded due to isolated DVT in the calf vein. Ninety-seven patients were enrolled in the study population.

Out of the 97 patients, 57 (58.8%) patients were male. The age of the patients ranged from 20 to 85 years, with a mean age of 60.4 years. A history of malignancy was the most common risk factor (25.8%), followed by immobility (15.5%), sepsis (2.1%) and trauma (2.1%).

All patients were treated with anticoagulants based on the clinical signs and symptoms before the ultrasound examination. Thirty-seven (38.1%) patients had a history of malignancy, or the clinical signs and symptoms of extensive DVT were treated by low molecular weight heparin (LMWH) 1 mg/kg subcutaneous q 12 h in the initial phase followed by long-term oral vitamin K antagonists (VKAs). Sixty (61.9%) patients were treated with VKAs alone (maintaining INR at 2.0–3.0) (Table 1). The timing of the repeat ultrasound in both groups ranged from 74 to 192 days (the median was 141 days). In the multiple median regression analysis, anticoagulation treatment was significantly associated with the maximum difference in lower extremity DVT thrombus thickness \( (p < 0.001) \). The adjusted coefficient (95% CI) of LMWH followed by VKAs compared with VKAs alone was \(-4\) (95% CI: \(-4.6, -3.4\)). In contrast, the timing of the repeat ultrasound was not significantly associated \( (p = 0.217) \) (Table 2).

Venous thrombi were predominantly located in the left lower extremities compared with the right lower extremities (62.9 vs 37.1%). The most common location was the popliteal vein (81.4%). However, the
maximum thrombus thickness change was found commonly in the proximal femoral vein (32.0%), followed by the common femoral vein (30.9%) and popliteal vein (18.6%). At the first diagnosis, 46.4% of thrombi were found in small veins; 63.9% were hyper-echoic thrombi, and 61.9% were eccentric thrombi (Table 3).

The thrombi found in dilated veins showed a significant decrease in the mean maximum difference in thickness of the thrombus compared with that of thrombi found in small veins: 4 mm vs. 0 mm (Coef. = 3, 95% CI: 1.9, 4.1 and P-value < 0.001). Anechoic and hypoechoic thrombi showed a significant decrease in the mean maximum difference in thickness of the thrombus compared with that of hyperechoic thrombi, 5 mm vs 0 mm (Coef. = 4, 95% CI: 3.25, 4.74 and P-value < 0.001) and 3 mm vs 0 mm (Coef. = 2, 95% CI: 1.34, 42.66 and P-value < 0.001), respectively. Concentric thrombi showed a significant decrease in the mean maximum difference in thickness compared with that of eccentric thrombi: 4 mm vs. 0 mm (Coef. = 2, 95% CI: 1.45, 2.55 and P-value < 0.001). Results

**Fig. 2** Echogenicity of the thrombus: A Anechoic thrombus; The thrombus appears black on the screen. B Hypoechoic thrombus; The thrombus appears grey on the screen. C Hyperechoic thrombus; The thrombus appears white on the screen. a = superficial femoral artery, v = femoral vein.

**Fig. 3** Shape of the thrombus: A concentric thrombus; the thrombus causes total occlusion of the popliteal vein. B Eccentric thrombus; the thrombus causes partial occlusion and forms an obtuse angle with the venous wall. a = popliteal artery, v = popliteal vein.
of median regression analysis between morphologic findings and the maximum difference in thickness of the thrombus after adjustment by the anticoagulant treatment are shown in Table 4.

**Discussion**

The results of this study advocate the benefit of venous thrombus morphology classification by ultrasound apart from the first imaging modality for DVT diagnosis. Differences in the size, echogenicity and shape of venous thrombi show different responses to anticoagulant treatment. A concentric anechoic or hypoechoic thrombus, which causes dilatation of the affected vein, shows a statistically significant decrease in thrombus thickness compared with that of eccentric hyperechoic thrombi in retracted veins, which offers minimal to no change in thickness after anticoagulant treatment. No previous clinical studies have reported this issue. Most reviews of venous ultrasound after anticoagulation treatment have focused on the risk of recurrent VTE when residual thrombus occurs [6–8].

With knowledge of the natural history of thrombus formation, ultrasound may specify the age of the thrombus by the difference in morphology. Fibrinogen is converted to fibrin in 1 day, forming a mesh that traps platelets and red blood cells and produces a thrombus. The cross-linking of fibrin and the development of internal zones of hemolysis are responsible for the anechoic-hypoechogenicity of the thrombus. The newly

---

**Table 1** Clinical characteristics data of the study population

| Characteristics          | Sample (n = 97) |
|-------------------------|----------------|
| Gender, n (%)           |                |
| Male                    | 57 (58.8)      |
| Female                  | 40 (41.2)      |
| Age, mean (SD)          | 60.4 (46.6)    |
| Risk factor, n (%)      |                |
| Malignancy              | 25 (25.8)      |
| Immobility              | 15 (15.5)      |
| Sepsis                  | 2 (2.1)        |
| Trauma                  | 2 (2.1)        |
| Cardiac arrhythmia      | 1 (1)          |
| Hormonal treatment      | 1 (1)          |
| Obesity                 | 1 (1)          |
| Pregnancy               | 0 (0)          |
| Follow-up time, median (min-max) days | 141 (74–192) |
| Treatment, n (%)        |                |
| LMWH followed by VKAs   | 37 (38.1)      |
| VKAs alone              | 60 (61.9)      |

*DVT* Deep vein thrombosis, *LMWH* Low molecular weight heparin, *LMWH* Low molecular weight heparin, *VKAs* Vitamin K antagonists

**Table 2** Factor associated with maximum difference thickness of the thrombus

| Factor                             | Coef. (95% CI) | P value |
|------------------------------------|----------------|---------|
| Follow up time                     | 0.009 (−0.006, 0.025) | 0.217   |
| Treatment                          |                |         |
| Maximum difference thickness in LMWH followed by VKAs | −4 (−4.6, −3.4) | <0.001* |
| Maximum difference thickness in VKAs alone | 0              |         |

*LMWH* Low molecular weight heparin, *VKAs* Vitamin K antagonists

*P*-value <0.05 was considered statistically significant

**Table 3** Characteristic data of the venous thrombus

| Characteristics                              | Sample (n = 97) |
|---------------------------------------------|----------------|
| Side of cases showing DVT involvement, n (%)|                |
| Right                                       | 36 (37.1)      |
| Left                                        | 61 (62.9)      |
| Anatomic distribution of thrombi, n (%)     |                |
| Common femoral vein (CFV)                  | 62 (63.9)      |
| Proximal femoral vein (prox FV)             | 72 (74.2)      |
| Mid femoral vein (mid FV)                  | 71 (73.2)      |
| Distal femoral vein (dis FV)               | 74 (76.3)      |
| Popliteal vein (Pop)                       | 79 (81.4)      |
| Location at maximum thrombus thickness change, n (%) |            |
| Common femoral vein (CFV)                  | 30 (30.9)      |
| Proximal femoral vein (prox FV)             | 31 (32.0)      |
| Mid femoral vein (mid FV)                  | 8 (8.3)        |
| Distal femoral vein (dis FV)               | 10 (10.3)      |
| Popliteal vein (Pop)                       | 18 (18.6)      |
| Size of affected vein (relative to adjacent artery), n (%) |            |
| Increased size                             | 23 (23.7)      |
| Normal size                                | 29 (29.9)      |
| Decreased size                             | 45 (46.4)      |
| Echogenicity of thrombus, n (%)             |                |
| Anechoic                                    | 17 (17.5)      |
| Iso/hypoechoic                             | 18 (18.6)      |
| Hyperechoic                                | 62 (63.9)      |
| Shape of thrombus, n (%)                   |                |
| Concentric                                 | 37 (38.1)      |
| Eccentric                                  | 60 (61.9)      |

*DVT* Deep vein thrombosis
formed thrombus tends to obstruct the vein lumen and expand the venous diameter entirely. The thrombin net squeezes red blood cells and fluid components out of the thrombi during thrombus ageing [9–11]. The proportion of red blood cells in the thrombus decreases with time, and the ultrasound signal intensity is affected by the number of red blood cells in the thrombus. This accounts for the increased echogenic appearance of the aged thrombus [12]. In the following 2–8 weeks, the thrombus organizes or dissolves from balancing clot formation and degradation. A mixture of the hyperplastic response of the endothelium at the site of thrombus deposition and residual thrombus incorporated into the wall during the scarring or fibrotic response causes asymmetrical wall thickening or an eccentric thrombus. The affected vein is often retracted [9–11]. Therefore, an acute obstructing DVT is typically hypoechogenic-concentric shaped, and the vein lumen is dilated. In contrast, the residual thrombus in chronic DVT is often hyperechogenic-eccentric shaped and adheres to one side of the vein wall, and the vein lumen is small.

The thrombus is transformed from being composed predominantly of platelets to having a fibrin composition with replacement by dense connective tissue [13]. Therefore, anticoagulation cannot break apart the chronic thrombus [15]. An acute nonobstructing thrombus does not often cause dilatation of the affected vein. Chronic thrombi can be found in dilated veins, especially after the development of venous reflux. The concentric shape of the thrombus remains in the small vein when there is no recanalization. Furthermore, the differentiation of acute and chronic thrombi by morphology remains mainly qualitative and nonstandardized. The ageing of the thrombus and the treatment decision may be purely based on patient reporting of symptoms.

Ultrasound elastography for assessing thrombus stiffness is a quantitative method for determining thrombus age. Few clinical studies involving lower extremity ultrasound have reported the difference between acute and chronic thrombi’s median normalized strain magnitude [16]. The strain ratio of the chronic and subacute thrombosis groups was found to be higher than that of the acute thrombosis group (P < 0.001, < 0.05) [17]. Combining thrombus morphology and ultrasound elastography may enhance ultrasound accuracy in thrombus age determination and require further study.

In addition, the limitation of this investigation is that it was a single-centre, retrospective cohort study with a small study population. Approximately 60% of the study population was diagnosed by the clinical manifestation and received LMWH before the ultrasound examination. No recurrent DVT or increase in thrombus thickness was found in our study population. Therefore, the value of differentiating thrombus morphology in follow-up ultrasound after anticoagulant treatment was not discovered.

**Conclusion**

The anticoagulant treatment with LMWH followed by VKAs shows a significant decrease in lower extremity

---

**Table 4** Correlation of morphologic sonographic findings and maximum difference in thrombus thickness after adjustment by treatment

| Morphologic findings                  | Maximum difference thickness (min-max) mm | Coef. (95% CI) | P Value |
|---------------------------------------|------------------------------------------|---------------|---------|
| **Size of the affected vein (relative to adjacent artery)** |                                          |               |         |
| Increased size                        | 4 (0–12)                                 | 3 (1.90, 4.10) | < 0.001*|
| Normal size                           | 1 (1–6)                                  | 0 (0.00, 0.82) | 1.00    |
| Decreased size                        | 0 (0–2)                                  | 0             |         |
| **Echogenicity of the thrombus**      |                                          |               |         |
| Anechoic                              | 5 (0–8)                                  | 4 (3.25, 4.74) | < 0.001*|
| Iso/hypoechoic                        | 3 (0–12)                                 | 2 (1.34, 2.66) | < 0.001*|
| Hyperechoic                           | 0 (0–2)                                  | 0             |         |
| **Shape of the thrombus**             |                                          |               |         |
| Concentric                            | 4 (1–12)                                 | 2 (1.45, 2.55) | < 0.001*|
| Eccentric                             | 0 (0–2)                                  | 0             |         |

* P-value <0.05 was considered statistically significant
DVT thrombus thickness compared with VKAs alone. After adjustment by treatment, the morphologic finding of acute thrombi (concentric, anechoic/hypoechoic and dilated vein) shows a significantly decreased thickness than the morphologic finding of chronic thrombi (eccentric, hyperechoic and retracted vein). Although the chronic thromb show minimal to no change in thickness, the increase in thickness or recurrent DVT did not occur after anticoagulant treatment.

**Abbreviations**

VTE: Venous thromboembolism; DVT: Deep venous thrombosis; PE: Pulmonary embolism; PTP: Pretest probability; CFV: Common femoral vein; LMWH: Low molecular weight heparin; VKAs: Vitamin K antagonists

**Acknowledgements**

We would like to thank the following doctors for taking part in treating patients with DVT: Dr. Gorawee Tepsamirthiporn and Dr. Nutsiri Kintirapong from the Department of Surgery, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand.

**Authors' contributions**

Dr. Tanapon Panpikoon, Dr. Wisanu Phattarapruksa, Dr. Tharintorn Treeist, Dr. Chinnarat Bua-ngam, Dr. Kaewpitha Pichitpichatkul and Dr. Apichaya Siriprachyakul designed and conducted this study, including patient recruitment, data collection and data analysis. Dr. Wisanu Phattarapruksa, Dr. Kaewpitha Pichitpichatkul and Dr. Apichaya Siriprachyakul prepared the manuscript draft with important intellectual input from Dr. Tanapon Panpikoon, Dr. Tharintorn Treeist and Dr. Chinnarat Bua-ngam. All authors approved the final manuscript. The department of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand, provided statistical support in analyzing the data.

**Funding**

No funding was received for this work.

**Availability of data and materials**

Not applicable.

**Declarations**

**Ethics approval and consent to participate**

Number COA. MURA2020/1629, Human Research Ethics Committee, Faculty of Medicine Ramathibodi Hospital, Mahidol University.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Received** 22 April 2021  **Accepted** 28 November 2021  **Published online** 14 December 2021

**References**

1. Nisio MD, Es NV, Buller HR. Deep vein thrombosis and pulmonary embolism. Lancet. 2016;388:3060–73.

2. Lim W, Le Gal G, Bates HM, Righini M, Haramati LB, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. Blood advances. 2018;2:3226–56.

3. Pollack CV, Schreiber D, Goldhaber SZ, Slattery D, Fanikos J, O’Neil BJ, et al. Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (multicenter emergency medicine pulmonary embolism in the RealWorld registry). J Am Coll Cardiol. 2011;57(6):700–6.

4. Mazzolai L, Aboyans V, Ageno W, Agnelli G, Alaties A, Bauersachs R, et al. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European society of cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J. 2017;0:1–14.

5. Le Gal G, Kovacs MJ, Carrier M, Do K, Kahn SR, Wells PS, et al. Validation of a diagnostic approach to exclude recurrent venous thromboembolism. J Thromb Haemost. 2009;7:752–9.

6. Pandorini P, Sensing AW, Prins MH, Bernardi E, Marchioni A, Bagatella P, et al. Residual venous thrombolysis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med. 2002;137:955–60.

7. Piovella F, Crippa L, Barone M, Vigano D’Angelo S, Serafini S, Galli L, et al. Normalization rates of compression ultrasonography in patients with first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis. Haematologica. 2002;87:515–22.

8. Young L, Ockelford P, Miline D, Rolfe-vyon V, Mckelvie S, Harper P. Post-treatment residual thrombus increases the risk of recurrent deep vein thrombosis and mortality. J Thromb Haemost. 2006;4:1919–24.

9. Karande GT, Hedgire SS, Sanchez Y, Ballyan V, Mishra V, et al. Advanced imaging in acute and chronic deep vein thrombosis. Cardiovascular diagnosis and therapy. 2016;493–507.

10. Dupuy DE. Venous US of lower extremity deep venous thrombosis. Radiographics. 2000;20:1195–200.

11. Leslie MS, Joshua C, Ulrike MH. Ultrasound diagnosis of lower extremity venous thrombosis. In: John SP, Joseph FP, editors. Introduction to vascular Sonography. 6th ed. Philadelphia: Elsevier Saunders; 2012. p. 377–95.

12. Fang J, Wu YL, Chen CK, Tsui PH. Discrimination between newly formed and aged thrombi using empirical mode decomposition of ultrasound b-scan image. Biomed Res Int. 2015;2015:403293 Epub 2015 Jan 28.

13. Peter H, Alex W, Mark S, Andrew F, Yash P, Nirvikar D, et al. Elastography techniques in the evaluation of deep vein thrombosis. Cardiovasc Diagn Ther. 2017;7(Suppl 3):S228–45.

14. Büller HR, Agnelli G, Hull RD, Myers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(suppl):401S–28S.

15. Murphy TP, Cronan JJ. Evolution of deep venous thrombosis: a prospective evaluation with US. Radiology. 1990;177:543–8.

16. Rubin JM, Xie H, Kim K, et al. Sonographic elasticity imaging of acute and chronic deep venous thrombosis in humans. J Ultrasound Med. 2006;25:1179–86.

17. Yi X, Wei X, Wang Y, et al. Role of real-time elastography in assessing the stage of thrombus. Int Angiol. 2017;36:59–63.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.